Image from Google Jackets

Prevalence of Psychoactive Substance use Amongst Patients with Schizophrenia at Mirembe Out-Patient Department.

By: Contributor(s): Material type: TextTextPublisher number: Wurzburg Road 35, BMC Premises, Post Code: 33102: P. O. Box 1464, Mwanza – Tanzania: Phone: +255 28 298 3384: Fax: +255 28 298 3386: Email: vc@bugando.ac.tz: www.bugando.ac.tzLanguage: English Language: Kiswahili Publication details: Mwanza, Tanzania: Catholic University of Health and Allied Sciences [CUHAS – Bugando] : ©2014Description: 35 Pages; Includes References and AppendiciesSubject(s): Summary: Abstract: Background: Schizophrenia is psychotic disorder the predominantly affects individual’s emotions, thought, perception and behavior the presents with delusions, hallucinations, disorganized speech, disorganized behavior and negative symptoms such as alogia, avolition and affective flattening. Objective: To determine the prevalence of substance use amongst Schizophrenia patients. Methodology: This is cross-sectional study that involves interviewing 198 participants both male and female aged 18-45 years at the Out-patient Department at Mirembe Hospital in Dodoma, Tanzania using structured questionnaire and the results will be interpreted using data software. Results: Amongst the 198 participants recruited; 87 were female and 111 were male. 55 out of the 198 (27.8%) participants admitted to use substance. Out of these 55 substance users; 39 (70.9%) were male and 16 (29.1%) of them were female. In addition to that 22 out of 55 (40%) participants who use substance reported to be using alcohol and others were tasting Nicotine/cigarette, marijuana. Bhang and cocktail of substances. None of them reported Heroin and cocaine use. Out 45 of the participants in the study admitted to have poor compliance to medications; 32 out of the 45 (71.1%) admitted to use substance. Conclusion: Substance use in Schizophrenia patients is also common and should be considered as among the contributory factors for worsening of the illness amongst these patients especially amongst Male patients.
Item type: UNDERGRADUATE DISSERTATIONS
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Collection Status Barcode
UNDERGRADUATE DISSERTATIONS MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO NFIC 1 UD0488
Total holds: 0

Abstract:

Background: Schizophrenia is psychotic disorder the predominantly affects individual’s emotions, thought, perception and behavior the presents with delusions, hallucinations, disorganized speech, disorganized behavior and negative symptoms such as alogia, avolition and affective flattening.

Objective: To determine the prevalence of substance use amongst Schizophrenia patients.

Methodology: This is cross-sectional study that involves interviewing 198 participants both male and female aged 18-45 years at the Out-patient Department at Mirembe Hospital in Dodoma, Tanzania using structured questionnaire and the results will be interpreted using data software.

Results: Amongst the 198 participants recruited; 87 were female and 111 were male. 55 out of the 198 (27.8%) participants admitted to use substance. Out of these 55 substance users; 39 (70.9%) were male and 16 (29.1%) of them were female. In addition to that 22 out of 55 (40%) participants who use substance reported to be using alcohol and others were tasting Nicotine/cigarette, marijuana. Bhang and cocktail of substances. None of them reported Heroin and cocaine use. Out 45 of the participants in the study admitted to have poor compliance to medications; 32 out of the 45 (71.1%) admitted to use substance.

Conclusion: Substance use in Schizophrenia patients is also common and should be considered as among the contributory factors for worsening of the illness amongst these patients especially amongst Male patients.

There are no comments on this title.

to post a comment.
Share
Catholic University of  Health and Allied Sciences - CUHAS
Directorate of ICT @ 2024